12:00 AM
 | 
Mar 30, 2015
 |  BC Week In Review  |  Clinical News  |  Regulatory

Akynzeo netupitant/palonosetron regulatory update

EMA’s CHMP recommended approval of Akynzeo netupitant/palonosetron (NEPA) from Helsinn to prevent acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy or with moderately emetogenic cancer chemotherapy. The...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >